CLINICAL TRIALS PROFILE FOR PFIZER-E

All Clinical Trials for PFIZER-E

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000159 ↗	Sorbinil Retinopathy Trial (SRT)	Completed	National Eye Institute (NEI)	Phase 3	1983-08-01	To evaluate the safety and efficacy of the investigational drug sorbinil, an aldose reductase inhibitor, in preventing the development of diabetic retinopathy and neuropathy in persons with insulin-dependent diabetes.
NCT00000708 ↗	Multi-center Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	N/A	1969-12-31	To compare the safety and effectiveness of fluconazole (FCZ) and amphotericin B (AMB), alone or in combination with flucytosine (FLC), as treatment for acute cryptococcal meningitis in patients who have not been treated previously or who have relapsed after a previous successful treatment. Cryptococcal meningitis is an important cause of disease and death among patients with AIDS. Usually AMB is given either alone or with FLC to patients with this infection, but these treatments are not always effective and both have toxic effects. Animal studies and preliminary studies in humans show that FCZ is active in cryptococcal meningitis and suggest that it may be less toxic than either AMB or FLC.
NCT00036270 ↗	Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane	Completed	Pfizer	Phase 3	2001-08-01	To compare the effects of exemestane for 5 years versus tamoxifen and exemestane given sequentially over 5 years in the adjuvant treatment of postmenopausal women with early breast cancer. This Pfizer sponsored trial is part of an international collaboration of investigators conducting 7 similar yet independent studies in 9 countries. This study is designed to be part of the larger TEAM trial where the data from these 7 studies will be combined. A pre-specified analysis of the pooled data will be conducted.
NCT00088283 ↗	Pegaptanib Sodium Compared to Sham Injection in Patients With Recent Vision Loss Due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)	Completed	Pfizer	Phase 2	2004-05-01	Eyetech Pharmaceuticals Inc. and Pfizer, Inc. are studying an investigational drug, MacugenTM, for the possible treatment of CRVO. An investigational drug is one that has not been approved by the U.S. Food and Drug Administration (FDA). This investigational drug may slow the growth of abnormal blood vessels in the eye and may reduce tissue swelling in the eye. The purpose of this study is to compare the safety and efficacy of a Macugen™ injection to a "pretend" injection. In addition, the purpose of this study is to measure the action of the study drug in the body over a period of time and to check for the presence of the study drug in your blood (called pharmacokinetics or PK). This study will involve approximately 90 people. People who decide to participate will have an equal chance (1 in 3) to receive one of three study injections, two of which are Macugen™ and one of which is a "pretend" injection.
NCT00088283 ↗	Pegaptanib Sodium Compared to Sham Injection in Patients With Recent Vision Loss Due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)	Completed	Eyetech Pharmaceuticals	Phase 2	2004-05-01	Eyetech Pharmaceuticals Inc. and Pfizer, Inc. are studying an investigational drug, MacugenTM, for the possible treatment of CRVO. An investigational drug is one that has not been approved by the U.S. Food and Drug Administration (FDA). This investigational drug may slow the growth of abnormal blood vessels in the eye and may reduce tissue swelling in the eye. The purpose of this study is to compare the safety and efficacy of a Macugen™ injection to a "pretend" injection. In addition, the purpose of this study is to measure the action of the study drug in the body over a period of time and to check for the presence of the study drug in your blood (called pharmacokinetics or PK). This study will involve approximately 90 people. People who decide to participate will have an equal chance (1 in 3) to receive one of three study injections, two of which are Macugen™ and one of which is a "pretend" injection.

Clinical Trial Conditions for PFIZER-E

Condition Name

Condition Name for PFIZER-E
Intervention	Trials
Healthy	70
Schizophrenia	10
Healthy Volunteers	10
Hypertension	7

Condition MeSH

Condition MeSH for PFIZER-E
Intervention	Trials
Malnutrition	16
Breast Neoplasms	12
Schizophrenia	11
Diabetes Mellitus	11

Clinical Trial Locations for PFIZER-E

Trials by Country

Trials by Country for PFIZER-E
Location	Trials
United States	588
Italy	154
India	66
Brazil	49
Canada	46

Trials by US State

Trials by US State for PFIZER-E
Location	Trials
California	39
Texas	39
Florida	31
New York	30
Connecticut	26

Clinical Trial Progress for PFIZER-E

Clinical Trial Phase

Clinical Trial Phase for PFIZER-E
Clinical Trial Phase	Trials
Phase 4	46
Phase 3	38
Phase 2/Phase 3	5

Clinical Trial Status

Clinical Trial Status for PFIZER-E
Clinical Trial Phase	Trials
Completed	175
Terminated	44
Recruiting	34

Clinical Trial Sponsors for PFIZER-E

Sponsor Name

Sponsor Name for PFIZER-E
Sponsor	Trials
Pfizer	122
Dr. Reddy's Laboratories Limited	14
Biogen	14

Sponsor Type

Sponsor Type for PFIZER-E
Sponsor	Trials
Industry	249
Other	200
NIH	8